Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced a collaboration with Biosero, a developer of ...

Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...

Barclays analyst Matt Miksic lowered the firm’s price target on Becton Dickinson (BDX) to $278 from $312 and keeps an Overweight rating on the ...

Becton Dickinson plans to invest more than $30M in 2025 to expand its manufacturing capacity for IV lines at its Utah plant.

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free ...

Becton Dickinson's (NYSE:BDX) stock is up by 4.3% over the past month. As most would know, long-term fundamentals ...

Oakmark Global Fund highlighted stocks like Becton, Dickinson and Company (NYSE:BDX) in the third quarter 2024 investor letter. Becton, Dickinson and Company (NYSE:BDX) develops and manufactures ...

Becton, Dickinson and Company is rated a hold due to low growth, valuation concerns, and underperformance compared to healthcare equipment peers. BDX's acquisition of Edwards Lifesciences ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.17% of ...

Becton, Dickinson and Company and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced a ...